S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.49
+1.81
+10.85%
BFRI · Biofrontera Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Biofrontera Inc (BFRI)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$0.80
-0.01
(-1.22%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.80
$0.80
$0.81
52-WEEK RANGE
$0.80
$0.56
$1.66
What's happening
- BFRI is down 1.22% today, trading at $0.80. — Live quote
- Volume today (1,510) is well below its 3-month average of 490,890. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.05 actual vs. $-0.11 estimated (+53.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BFRI
+41.35%
vs S&P 500
+28.95%
1-YEAR RETURN
BFRI
-16.07%
vs S&P 500
-31.44%
6-MONTH RETURN
BFRI
-23.99%
3-MONTH RETURN
BFRI
-23.27%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.05
Est. $-0.11
BEAT +53.3%
2026-04-26 (Q1 2026)
$-0.37
Est. $-0.12
MISS -215.4%
2026-01-26 (Q4 2025)
$0.48
Est. $0.20
BEAT +142.8%
2025-10-26 (Q3 2025)
$-0.62
Est. $-0.59
MISS -4.8%
Valuation Measures & Ratios
Enterprise Value4$11.9M
Forward P/E5656.95
PEG Ratio6—
Price / Sales (TTM1)0.26
Price / Book72.03
EV4 / Revenue0.26
EV4 / EBITDA—
Profit Margin-13.78%
Operating Margin-14.21%
Return on Equity (ROE8)3.79%
Return on Assets (ROA9)-27.43%
Avg Volume (3M)490,890
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $11.5M | $9.3M | $10.4M | $6.6M | $7.3M |
| P/E | -0.66 | -0.44 | -0.48 | -0.43 | -0.36 |
| Price/Sales | 0.30 | 0.27 | 0.31 | 0.19 | 0.22 |
| Price/Book | 1.93 | 1.53 | -4.02 | -1.42 | 15.63 |
| EV/Revenue | 0.18 | 0.09 | 0.21 | -0.02 | 0.17 |
| ROE | -290.95% | -344.78% | 846.38% | 331.04% | -4385.07% |
| ROA | -72.01% | -84.43% | -141.71% | -76.72% | -123.98% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short146,851
Change from Prior Settlement-68.41%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 32.9% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -13.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -16.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BFRI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M | $10.1M | $7.0M | $9.0M | $8.6M | $9.0M | $7.8M | $7.9M |
| Operating income | -$524.0K | -$4.3M | -$6.3M | -$5.1M | -$4.5M | -$5.0M | -$5.1M | -$5.5M |
| Net income | -$604.0K | -$4.8M | -$6.6M | -$5.3M | -$4.2M | -$5.7M | -$257.0K | -$10.4M |
| EPS (diluted) | $-0.05 | $-0.41 | $-0.62 | $-0.57 | $-0.47 | $-0.98 | $-0.05 | $-2.88 |
| EPS (basic) | $-0.05 | $-0.41 | $-0.62 | $-0.57 | $-0.47 | $-0.98 | $-0.05 | $-2.88 |
| Operating margin | -$4 | -$43 | -$90 | -$56 | -$53 | -$55 | -$65 | -$69 |
| Net margin | -$5 | -$47 | -$95 | -$59 | -$49 | -$63 | -$3 | -$132 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $24.1M | $24.8M | $28.6M | $15.4M | $20.1M | $16.6M | $22.1M | $18.5M |
| Total liabilities | $18.1M | $18.7M | $18.1M | $18.0M | $24.8M | $16.1M | $17.7M | $13.0M |
| Stockholders' equity | $6.0M | $6.1M | $10.5M | -$2.6M | -$4.7M | $469.0K | $4.4M | $5.5M |
| Total current assets | $12.4M | $13.2M | $18.1M | $14.4M | $18.8M | $15.3M | $20.7M | $16.9M |
| Total current liabilities | $10.5M | $10.9M | $11.9M | $12.6M | $19.7M | $11.0M | $12.0M | $11.0M |
| Cash & equivalents | $4.7M | $6.3M | $6.4M | $3.4M | $7.2M | $1.8M | $5.9M | $2.9M |
| Accounts receivable | $5.5M | — | $7.3M | — | — | — | — | — |
| Inventory | $1.1M | $1.2M | $1.4M | $4.3M | $4.0M | $6.5M | $6.6M | $6.5M |
| Property, plant & equipment | $2.1M | $2.2M | $2.2M | $20.0K | $37.0K | $59.0K | $80.0K | $82.0K |
| Intangible assets | $2.6M | $2.6M | $2.6M | $22.0K | $26.0K | $31.0K | $35.0K | $39.0K |
| Accounts payable | — | — | — | — | — | — | — | — |
| Accrued liabilities | — | $500.0K | — | — | — | — | $4.3M | $4.7M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $9.0K | $6.0K | $9.0K | $12.0K | $14.0K | $21.0K | $23.0K | $29.0K |
| Common stock & paid-in capital | $14.0K | $12.0K | $12.0K | $12.0K | $9.0K | $9.0K | $9.0K | $7.0K |
| Retained earnings | -$133.3M | -$132.7M | -$127.9M | -$133.6M | -$126.9M | -$121.6M | -$117.4M | -$116.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.7M | -$70.0K | -$2.4M | -$3.8M | -$3.0M | -$4.1M | -$1.0M | -$1.2M |
| Investing cash flow | $0 | -$5.0K | $3.0M | $1.0K | -$1.0K | -$3.0K | -$1.0K | $0 |
| Financing cash flow | — | — | $2.4M | $0 | $8.5M | — | $4.0M | -$298.0K |
| Free cash flow | -$1.7M | -$75.0K | -$2.4M | -$3.8M | -$3.0M | -$4.1M | -$1.0M | -$1.2M |
| Capital expenditures | $0 | $5.0K | -$1.0K | -$1.0K | $1.0K | $3.0K | $1.0K | $0 |
| Depreciation & amortization | $65.0K | $55.0K | $83.0K | — | $26.0K | $29.0K | $421.0K | — |
| Share-based compensation | $263.0K | $342.0K | $289.0K | $236.0K | $187.0K | $239.0K | $299.0K | $288.0K |
| Change in accounts receivable | $1.7M | -$3.4M | $4.3M | -$947.0K | -$88.0K | -$1.3M | $492.0K | $1.4M |
| Change in inventory | -$79.0K | -$307.0K | $872.0K | $301.0K | -$2.5M | -$119.0K | $147.0K | $2.6M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M |
| Operating income | -$11.3M | -$17.2M | -$22.7M | -$18.6M | -$25.2M |
| Net income | -$10.5M | -$17.8M | -$20.1M | -$640.0K | -$37.7M |
| EPS (diluted) | $-1.04 | $-3.22 | $-13.02 | $-0.61 | — |
| EPS (basic) | $-1.04 | $-3.22 | $-13.02 | $-0.61 | $-4.28 |
| Operating margin | -$27 | -$46 | -$67 | -$65 | -$105 |
| Net margin | -$25 | -$48 | -$59 | -$2 | -$156 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M |
| Stockholders' equity | $10.5M | $4.4M | $4.8M | $23.9M | $11.3M |
| Total current assets | $18.1M | $20.7M | $23.1M | $43.1M | $46.4M |
| Total current liabilities | $11.9M | $12.0M | $18.1M | $20.9M | $13.8M |
| Cash & equivalents | $6.4M | $5.9M | $1.3M | $17.2M | $24.5M |
| Inventory | $1.4M | $6.6M | $10.9M | $7.2M | $4.5M |
| Property, plant & equipment | $2.2M | $80.0K | $134.0K | $204.0K | $267.0K |
| Intangible assets | $2.6M | $35.0K | $2.6M | $3.0M | $3.5M |
| Accounts payable | — | — | — | $1.3M | $658.0K |
| Accrued liabilities | — | $4.3M | $4.5M | $10.9M | $9.7M |
| Short-term debt | — | — | $3.9M | — | — |
| Other non-current liabilities | $9.0K | $23.0K | $37.0K | $21.0K | $5.6M |
| Common stock & paid-in capital | $12.0K | $9.0K | $2.0K | $1.0K | $17.0K |
| Retained earnings | -$127.9M | -$117.4M | -$99.7M | -$79.5M | -$78.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | -$26.7M |
| Investing cash flow | $3.0M | -$3.0K | $619.0K | -$5.2M | -$11.0K |
| Financing cash flow | $10.8M | $14.8M | $8.4M | $14.0M | $43.2M |
| Free cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | — |
| Capital expenditures | $2.0K | $10.0K | $5.0K | $38.0K | — |
| Depreciation & amortization | $138.0K | $421.0K | — | — | — |
| Share-based compensation | $951.0K | $1.0M | $1.0M | $1.9M | $129.0K |
| Change in accounts receivable | $1.9M | $315.0K | $1.5M | $70.0K | $612.0K |
| Change in inventory | -$1.4M | -$4.2M | $3.8M | $2.8M | -$2.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BFRI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-05-18 to 2026-07-28
Recent transactions
- Most recent: Luebbert Hermann (CEO & Chairman) — Option exercise of 62,500 shares on 2026-07-28.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Luebbert Hermann | CEO & Chairman | Option exercise | 2026-07-28 | 62,500 |
| Leffler Eugene Frederick | Chief Financial Officer | Option exercise | 2026-07-28 | 31,250 |
| Monaco Erica L. | Chief Executive Officer | Option exercise | 2023-05-18 | 76,336 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-28 | Luebbert Hermann | CEO & Chairman | Option exercise | 62,500 | — |
| 2026-07-28 | Leffler Eugene Frederick | Chief Financial Officer | Option exercise | 31,250 | — |
| 2026-03-05 | Luebbert Hermann | CEO & Chairman | Option exercise | 137,500 | — |
| 2026-03-05 | Leffler Eugene Frederick | Chief Financial Officer | Option exercise | 87,500 | — |
| 2025-09-10 | Luebbert Hermann | CEO & Chairman | Option exercise | 137,500 | — |
| 2025-09-10 | Leffler Eugene Frederick | Chief Financial Officer | Option exercise | 87,500 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-28 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-28 | View on SEC.gov → |
| 2026-06-17 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-03-19 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-03-19 | 8-K | 2026-03-19 | View on SEC.gov → |
| 2026-03-09 | 8-K | 2026-03-09 | View on SEC.gov → |
| 2026-03-06 | 4 | 2026-03-04 | View on SEC.gov → |
Recent news
Headlines about BFRI (Biofrontera Inc.). Links open the publisher — we don’t host full articles.
-
Which of Upstream Bio (NASDAQ:UPB), Biofrontera (NASDAQ:BFRI), Aldeyra Therapeutics (NASDAQ:ALDX), KALA BIO (NASDAQ:KALA) or Inovio Pharmaceuticals (NASDAQ:INO) Is the Best Biotech or Pharma Gainer in Pre-Market?
kalkine.ca · 2026-10-16 -
Which of Circle8 Group (NASDAQ:CIRC), SAGTEC Global (NASDAQ:SAGT), Biofrontera (NASDAQ:BFRI), Merlin (NASDAQ:MRLN) or 20/20 Biolabs (NASDAQ:AIDX) Rose 9% to 10% in Pre-Market?
kalkine.ca · 2026-10-16 -
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
Yahoo · 2026-10-08 -
Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses
Benzinga · 2026-10-08 -
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Yahoo Finance · 2026-09-14 -
Biofrontera (BFRI) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-20 -
Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...
Yahoo Finance · 2026-08-13 -
Biofrontera outlines September 28, 2026 PDUFA date and expects sBCC launch in Q1 2027 amid ITC lamp remediation
Seeking Alpha · 2026-08-13
No headlines in this category right now — try “All”.